Ibrutinib Reactions 1680, p162 - 2 Dec 2017 Mild fatigue, easy bruising and atrial fibrillation: 2 case reports In a case series, two patients were described, out of whom a 73-year-old woman developed mild fatigue and easy bruising and a 77-year-old man developed atrial fibrillation during treatment with ibrutinib [route, time to reactions onsets and outcomes not stated]. Patient 1: A 73-year-old woman, who had a history of B-cell prolymphocytic leukaemia, was started on ibrutinib 420mg daily. She had also received rituximab and enoxaparin. Her treatment course with ibrutinib was complicated by mild fatigue and easy bruising. The treatment with ibrutinib was maintained. She remained on ibrutinib for 15 months. Patient 2: A 77-year-old man, who had a history of B-cell prolymphocytic leukaemia, was started on ibrutinib 420 mg/day. His relevant medical history included coronary artery disease and hypertension. He had also received unspecified antibiotics and steroids, bendamustine and rituximab. His treatment course with ibrutinib was complicated by an episode of atrial fibrillation, which required a brief discontinuation of ibrutinib therapy. Later, ibrutinib was restarted and his constitutional symptoms resolved with therapy. He remained on ibrutinib for 12 months. Author comment: "Therapy was complicated by mild fatigue and easy bruising, not requiring either dose adjustment or interruption." "The treatment course was complicated by an episode of atrial fibrillation which required a brief interruption of ibrutinib therapy." Gordon MJ, et al. Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia. British Journal of Haematology 179: 501-503, No. 3, Nov 2017. Available from: URL: http://doi.org/10.1111/bjh.14224 - USA 803284481 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial